TAOX — TAO Synergies Share News
0.000.00%
Last trade - 00:00- $25.07m
- $22.70m
- $0.30m
Brief: Tao Synergies Inc - Increases Tao Holdings to 54,058 Tokens
Brief: Tao Synergies Accelerates Decentralized AI Treasury Strategy With 42,111 Bittensor Tokens
Brief: Synaptogenix Renamed TAO Synergies, New Ticker "TAOX" for AI-Focused Crypto Strategy
Brief: Synaptogenix Announces Initial TAO Acquisition Under Crypto Treasury Strategy
Brief: Synaptogenix Says On June 8, Alan Tuchman Resigned As CEO And Director Of Co
Brief: Synaptogenix Launch Of Differentiated Cryptocurrency Treasury Strategy Focused Exclusively On AI Crypto Token 'TAO'
Brief: Synaptogenix Files For Prospectus Related To Resale Or Other Disposition From Time To Time Of Up To 11.9 Million Shares Of Common Stock- SEC Filing
Brief: Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Brief: Synaptogenix Announces FDA Authorization Of IND Application For Clinical Trial For Bryostatin-1 In Multiple Sclerosis
Brief: Biotech Synaptogenix Increases Stake In Psilocybin Drug Discovery Firm PsygaBio
Brief: Synaptogenix Announces Reverse Stock Split To Maintain Nasdaq Listing
U.S. STOCKS ON THE MOVE-Nvidia Corp, Royal Caribbean, Moderna
Brief: Synaptogenix Acquires Significant Stake In Cannasoul Analtyics Ltd.
Brief: Synaptogenix And Cleveland Clinic To Submit IND Application To FDA For Clinical Trial Of Bryostatin-1 In Multiple Sclerosis
Brief: Synaptogenix Inc Says On April 24 Received Notice Of Delisting Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Synaptogenix Provides Corporate Update And Outlines Potential Business Opportunities
Synaptogenix falls as Alzheimer's drug fails to meet mid-stage study goal
Brief: Synaptogenix Announces Topline Results From NIH-Sponsored Phase 2 Clinical Trial Of Bryostatin-1 For Advanced Alzheimer's Disease
Brief: Synaptogenix Announces $15 Million Private Placement With Existing Investors